JP2021501150A - 肝臓がんを治療するための組成物及び方法 - Google Patents

肝臓がんを治療するための組成物及び方法 Download PDF

Info

Publication number
JP2021501150A
JP2021501150A JP2020523323A JP2020523323A JP2021501150A JP 2021501150 A JP2021501150 A JP 2021501150A JP 2020523323 A JP2020523323 A JP 2020523323A JP 2020523323 A JP2020523323 A JP 2020523323A JP 2021501150 A JP2021501150 A JP 2021501150A
Authority
JP
Japan
Prior art keywords
pembrolizumab
administered
antigen
dose
laharparepbeck
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020523323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501150A5 (enExample
Inventor
ガンサート，ジェニファー・ロレーヌ
ムルガッパン，スワミナサン
ウルフ，マイケル・ケビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2021501150A publication Critical patent/JP2021501150A/ja
Publication of JP2021501150A5 publication Critical patent/JP2021501150A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020523323A 2017-10-27 2018-10-26 肝臓がんを治療するための組成物及び方法 Pending JP2021501150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578071P 2017-10-27 2017-10-27
US62/578,071 2017-10-27
PCT/US2018/057731 WO2019084418A1 (en) 2017-10-27 2018-10-26 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER

Publications (2)

Publication Number Publication Date
JP2021501150A true JP2021501150A (ja) 2021-01-14
JP2021501150A5 JP2021501150A5 (enExample) 2021-12-02

Family

ID=64453576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523323A Pending JP2021501150A (ja) 2017-10-27 2018-10-26 肝臓がんを治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US20200353022A1 (enExample)
EP (1) EP3700544A1 (enExample)
JP (1) JP2021501150A (enExample)
KR (1) KR20200078483A (enExample)
CN (1) CN111278448A (enExample)
AR (1) AR113805A1 (enExample)
AU (1) AU2018355519A1 (enExample)
BR (1) BR112020007494A2 (enExample)
CA (1) CA3075294A1 (enExample)
MX (1) MX2020003388A (enExample)
SG (1) SG11202002123XA (enExample)
TW (1) TWI817958B (enExample)
WO (1) WO2019084418A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
BR112019022488A2 (pt) * 2017-04-28 2020-06-16 Merck Sharp & Dohme Corp. Biomarcadores para terapêutica do câncer
CN114191547A (zh) * 2021-12-23 2022-03-18 中山大学 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用
WO2025085538A1 (en) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Alarmin binding molecules and treatment of cancer
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
CN120555373A (zh) * 2014-07-16 2025-08-29 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
CN108778301A (zh) * 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
KR20190112263A (ko) * 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
BR112019022488A2 (pt) * 2017-04-28 2020-06-16 Merck Sharp & Dohme Corp. Biomarcadores para terapêutica do câncer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUMMER, R. ET AL.: "Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII, vol. 66, no. 6, JPN6022042279, 25 February 2017 (2017-02-25), pages 683 - 695, XP036244898, ISSN: 0005104146, DOI: 10.1007/s00262-017-1967-1 *
HARRINGTON, K. J. ET AL.: "Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-der", EXPERT REVIEW OF ANTICANCER THERAPY, vol. 15, no. 12, JPN6022042284, 2015, pages 1389 - 1403, ISSN: 0005274956 *
RIBAS, A. ET AL.: "Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy", CELL, vol. 170, no. 6, JPN6022042281, 7 September 2017 (2017-09-07), pages 1109 - 1119, ISSN: 0005104147 *
TRUONG, P. ET AL.: "Hepatocellular Carcinoma Responsive to Pembrolizumab", CUREUS, vol. 8, no. 6, JPN6023028771, 2016, pages 631, ISSN: 0005274957 *

Also Published As

Publication number Publication date
KR20200078483A (ko) 2020-07-01
RU2020111709A (ru) 2021-11-29
CA3075294A1 (en) 2019-05-02
SG11202002123XA (en) 2020-04-29
RU2020111709A3 (enExample) 2022-04-26
AR113805A1 (es) 2020-06-10
US20200353022A1 (en) 2020-11-12
BR112020007494A2 (pt) 2020-11-03
EP3700544A1 (en) 2020-09-02
CN111278448A (zh) 2020-06-12
AU2018355519A1 (en) 2020-03-26
WO2019084418A1 (en) 2019-05-02
TWI817958B (zh) 2023-10-11
TW201922273A (zh) 2019-06-16
MX2020003388A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
US12083112B2 (en) Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US20220324979A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
IL270253B1 (en) Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them
TWI817958B (zh) 用於治療肝癌之組合物及方法
CN106456753A (zh) 用于治疗癌症的pd‑1拮抗剂和ido1抑制剂的组合
US20180044418A1 (en) Combination of a pd-1 antagonist and vorinostat for treating cancer
JP2024001071A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
JP7240512B2 (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
RU2802962C2 (ru) Композиции и способы лечения рака печени
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
EP4494654A1 (en) Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
JP2025504278A (ja) 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法
JP2025534656A (ja) 抗ｐｄ１抗体の皮下投与による癌を治療するための組成物および方法
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
CN116209466A (zh) 抗pd-1抗体在治疗鼻咽癌中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305